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ABSTRACT
Osteoarthritis (OA) progresses via a feed-forward cycle in which infl ammation leads to the up-regulation of catabol-
ic enzymes that cleave the extracellular matrix (ECM) components. Fragments of ECM molecules hyaluronic acid 
and collagen type II further stimulate infl ammation. The degradation of aggrecan is a critical early event in OA due 
to aggrecan’s ability to protect other ECM components from degradation and support the compressive strength of 
cartilage. Characterized herein is an aggrecan mimic’s (mAGC) ability to replace the functions of native aggrecan 
and halt the progression of OA. We examine mAGC in both ex vivo cartilage tissue models and in vivo animal 
models. Aggrecan-depleted cartilage plugs had only ~30% of the compressive strength of intact plug. mAGC was 
able to diffuse into the cartilage tissue and restore the compressive strength to 90% of the intact healthy cartilage. 
Depletion of aggrecan also resulted in an increase in catabolic gene expression by chondrocytes that was further 
amplifi ed with additional infl ammatory stimuli. Treatment with mAGC resulted in chondrocyte gene expression of 
catabolic enzymes at the same lower levels as healthy intact cartilage, both with and without infl ammatory stim-
ulation over 21 days. Intact cartilage plugs exposed to osteoarthritic synovial fl uid resulted in high degradation of 
ECM components as measured by release into the culture media over an 8-day period. A single pretreatment with 
mAGC decreased this degradation to levels similar to those in healthy cultured controls. Further, infl ammation and 
catabolic enzymatic gene expression was lowered in treated plugs to near healthy levels, even in the presence 
of the infl ammatory and enzyme-rich synovial fl uid. The data indicates that by providing robust protection against 
degradation and restoring the mechanical environment, the pro-infl ammatory signals that cause upregulation of 
the degrading enzymes are decreased. In an aggressive rat model, mAGC was able to keep catabolic enzyme 
levels closer to healthy levels, preserve the proteoglycan content of cartilage tissue, and decrease bone loss when 
compared with untreated controls. In a nontraumatic guinea pig model, mACG suppressed the progression of OA. 
This study provides the ground-work for development of an intra-articular therapy that reduces fragmentation of 
key extracellular matrix components and restores the mechanical environment of the cartilage tissue, resulting in 
decrease in infl ammation and catabolic enzyme production. The therapy has the potential to promote a healthy 
environment for future tissue regeneration.
